Searle (SEARL) Stock Overview
Manufactures and sells pharmaceutical and other consumer products in Pakistan, Sri Lanka, Myanmar, Cambodia, Vietnam, Iraq, Oman, Afghanistan, Tajikistan, Laos, Kenya, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SEARL from our risk checks.
SEARL Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
The Searle Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨92.89 |
| 52 Week High | PK₨129.32 |
| 52 Week Low | PK₨54.00 |
| Beta | 0.57 |
| 1 Month Change | 12.50% |
| 3 Month Change | -3.06% |
| 1 Year Change | 51.86% |
| 3 Year Change | 11.28% |
| 5 Year Change | -25.46% |
| Change since IPO | 2,323.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| SEARL | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 2.7% | 4.5% | 1.7% |
| 1Y | 51.9% | 85.9% | 45.7% |
Return vs Industry: SEARL underperformed the PK Pharmaceuticals industry which returned 96.8% over the past year.
Return vs Market: SEARL matched the PK Market which returned 51.3% over the past year.
Price Volatility
| SEARL volatility | |
|---|---|
| SEARL Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 7.4% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in PK Market | 10.2% |
| 10% least volatile stocks in PK Market | 4.6% |
Stable Share Price: SEARL has not had significant price volatility in the past 3 months compared to the PK market.
Volatility Over Time: SEARL's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | 4,026 | Syed Ahmed | searlecompany.com |
The Searle Company Limited, together with its subsidiaries, manufactures and sells pharmaceutical and other consumer products in Pakistan, Sri Lanka, Myanmar, Cambodia, Vietnam, Iraq, Oman, Afghanistan, Tajikistan, Laos, Kenya, and internationally. The company offers pharmaceutical products, such as analgesics and muscle relaxants, anti-allergy and anti-tussive, anti-anemic, anti-chelating, anti-infective, anti-neoplastic, anti-thrombotic, cardiovascular, endocrinology and metabolism, gastrointestinal, gynecology, urology and sex hormones, hepatology, hospital solutions, neurology and psychiatry, orthopedics and rheumatology, respiratory, and systemic-hormones. It also provides biopharmaceutical products; nutraceutical products, such as herbal supplements, probiotics and enzymes, and vitamins and minerals; nutrition products, including baby cereals; consumer products; consumer products; and medical devices and disposables for blood transfusion, critical care and anesthesia, IV administration, ophthalmology, and renal care, as well as surgical gloves.
The Searle Company Limited Fundamentals Summary
| SEARL fundamental statistics | |
|---|---|
| Market cap | PK₨47.51b |
| Earnings (TTM) | PK₨1.97b |
| Revenue (TTM) | PK₨29.12b |
Is SEARL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SEARL income statement (TTM) | |
|---|---|
| Revenue | PK₨29.12b |
| Cost of Revenue | PK₨15.18b |
| Gross Profit | PK₨13.94b |
| Other Expenses | PK₨11.96b |
| Earnings | PK₨1.97b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.86 |
| Gross Margin | 47.86% |
| Net Profit Margin | 6.78% |
| Debt/Equity Ratio | 24.5% |
How did SEARL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/12 11:22 |
| End of Day Share Price | 2025/06/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Searle Company Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yusra Beg Farhan | Intermarket Securities Limited |
| Hamza Hanif | Taurus Securities Ltd |
| Hania Nadeem | Taurus Securities Ltd |